by Myariyoblog

August 26th 2024.

The purpose of the injection is to "teach" the immune system to recognize and destroy cancer cells, as well as to prevent their reappearance.

Phase I clinical trials have begun in 34 research centers in the UK, the US, Germany, Hungary, Poland, Spain, and Turkey. The trials involve patients with different stages of the disease

The groundbreaking phase I clinical trials for an mRNA vaccine targeting lung cancer have officially started across 34 research centers in the UK, the US, Germany, Hungary, Poland, Spain, and Turkey.

The vaccine, known as BNT116 and developed by BioNTech, is designed to "teach" the immune system to recognize and eliminate cancer cells, with the added potential to prevent their recurrence.

Photo Credit:Trials of mRNA Vaccine Against Lung Cancer Begin in Seven Countries

This innovative approach is being tested on 130 patients with various stages of non-small cell lung cancer (NSCLC), which is the most common and deadliest form of the disease.

The mRNA technology behind this vaccine works by providing cells with the genetic instructions to produce specific proteins that trigger an immune response against cancer cells, without harming healthy cells.

This trial marks a significant step forward in cancer treatment, offering new hope to patients with advanced lung cancer who have historically faced poor prognoses.

Experts are optimistic about the potential of this vaccine, with clinicians hailing it as a "groundbreaking" advancement that could lead to life-saving treatments in the near future.